RESUMO
OBJECTIVE: Long noncoding RNA linc-ITGB1 (linc-ITGB1) was reported to serve as a tumor promoter in breast cancer (BC). However, the clinical significance of linc-ITGB1 has not been reported. The present study aimed to determine the relationship between linc-ITGB1 expression and clinicopathological features and survival. PATIENTS AND METHODS: qRT-PCR was used to quantify the expression levels of linc-ITGB1 in BC and adjacent non-cancerous breast tissues. The X2 test was performed to determine the associations between linc-ITGB expression and the clinicopathological characters. The overall survival time (OS) and disease-free survival (DFS) were collected by follow-up and analyzed by Kaplan-Meier analysis. Multivariate Cox regression analysis was used to identify the independent risk factors for BC. RESULTS: The results showed that linc-ITGB1 levels were lower in tumor tissues of BC patients in comparison to adjacent non-cancerous breast tissues (p < 0.001). Linc-ITGB1 expression was significantly associated with lymph node metastasis, pathological differentiation and TNM stage (all p < 0.05). Furthermore, Kaplan-Meier analysis demonstrated that high-linc-ITGB1 expression level was associated with poorer OS (p = 0.006) and DFS (p = 0.003). Cox proportional hazards risk analysis demonstrated that linc-ITGB1 was an independent predictor for both OS (p = 0.004) and DFS (p = 0.002) in BC. CONCLUSIONS: These results indicated, for the first time, that linc-ITGB1 be a potential biomarker in the prognosis of BC.
Assuntos
Biomarcadores Tumorais/biossíntese , Neoplasias da Mama/genética , Peptídeos e Proteínas de Sinalização Intracelular/biossíntese , Proteínas de Membrana/biossíntese , RNA Longo não Codificante/biossíntese , Proteínas Adaptadoras de Transdução de Sinal , Adulto , Idoso , Biomarcadores Tumorais/genética , Intervalo Livre de Doença , Feminino , Humanos , Peptídeos e Proteínas de Sinalização Intracelular/genética , Estimativa de Kaplan-Meier , Metástase Linfática/genética , Proteínas de Membrana/genética , Pessoa de Meia-Idade , Prognóstico , RNA Longo não Codificante/genética , Análise de Sobrevida , Regulação para Cima/genéticaRESUMO
A rapid, sensitive and simple to operate high performance liquid chromatographic method for the simultaneous determination of carbamazepine (CBZ) and its metabolite (10,11-epoxide carbamazepine, ECBZ) in serum has been developed. The sample was extracted with ethyl acetate. The extract was evaporated to dryness and taken up with the mobile phase. Separation of CBZ and ECBZ was achieved by reversed phase chromatography using a mobile phase consisting of methanol-water (1:1) at flow rate of 0.8 ml/min on a 5 microns YWG C-18 column. Eluent was monitored at 214 nm. The method has a good linearity. The recoveries of CBZ and ECBZ were found to be 99.7% +/- 2.45 and 97.3% +/- 4.20 respectively. Precision studies for both within day and day-to-day at different concentrations provided CV values of less than 6%. Some commonly used anticonvulsants can be determined in the same procedure without interference. This method well adapted to the therapeutic monitoring of CBZ treated patients, as well as for pharmacokinetic studies.
